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Abstract
Background: Mesothelioma is a highly fatal cancer that is caused by exposure to asbestos fibres.
In many populations, the occurrence of mesothelioma is monitored with the use of mortality data
from death certification. We examine certified causes of death of patients who have been
diagnosed with mesothelioma, and assess the validity of death certification data as a proxy for
mesothelioma incidence.
Methods: We extracted mesothelioma registrations in the South East of England area between
2000 and 2004 from the Thames Cancer Registry database. We retained for analysis 2200 patients
who had died at the time of analysis, after having excluded seven dead cases where the causes of
death were not known to the cancer registry. The 2200 deaths were classified hierarchically to
identify (1) mesothelioma deaths, (2) deaths certified as lung cancer deaths or (3) deaths from
unspecified cancer, and (4) deaths from other causes.
Results: 87% of the patients had mesothelioma mentioned on the death certificate. 6% had no
mention of mesothelioma but included lung cancer as a cause of death. Another 6% had no mention
of mesothelioma or lung cancer, but included an unspecified cancer as a cause of death. Lastly, 2%
had other causes of death specified on the death certificate.
Conclusion:  This analysis suggests that official mortality data may underestimate the true
occurrence of mesothelioma by around 10%.
Background
Mesothelioma is a rare form of cancer that arises from the
pleura or, less often, from the peritoneum. The disease is
almost always fatal and the median time between diagno-
sis and death is less than one year [1,2]. Mesothelioma is
strongly associated with occupational exposure to asbes-
tos fibres. Industries with high exposure to asbestos in the
past included mining, shipyard working and asbestos
cement manufacture.
The annual numbers of mesothelioma deaths in Great
Britain increased 12-fold in the period from 1968 to
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2001[3] and an epidemiological model that incorporated
the historical use of asbestos suggested that the annual
numbers of deaths will continue to rise to a peak at
around 1950–2400 deaths per year in 2011–2015.
The aim of this analysis was to examine the certified
causes of death of patients diagnosed with mesothelioma,
and assess the validity of mortality data as a proxy for data
on mesothelioma incidence.
Methods
Initially, we extracted the numbers of mesothelioma can-
cer registrations and mesothelioma deaths nationally for
2004 from the Cancer Information System (CIS), which
provides cancer registration and cancer mortality data
from the whole of England.
Thereafter, we extracted cancer registrations of patients
diagnosed with mesothelioma in the South East of Eng-
land area between 2000 and 2004 from the Thames Can-
cer Registry database. Patients who had cause of death
specified on the death certificate were identified and used
for the analysis.
The deaths were classified hierarchically as follows: Firstly,
we identified death certificates that mentioned mesotheli-
oma as one of the causes of death. Secondly, among the
remaining death certificates, we identified those that men-
tioned lung cancer as a cause of death. Third, among the
now remaining death certificates, we identified those that
mentioned an unspecified cancer as a cause of death. Last,
there remained a group of death certificates that included
no mention of mesothelioma, lung cancer or unspecified
cancer.
Results
In 2004 there were 1847 cases of mesothelioma and 1629
deaths from mesothelioma in the whole of England.
These numbers, which are based on nationwide cancer
registration and official mortality statistics, respectively,
suggest crudely that around 88% of mesothelioma cases
die from the disease. An analysis of one area of England
was therefore set up to explore this in more detail using
individually linked information on mesothelioma inci-
dence and the causes of death in these patients.
There were 2433 patients diagnosed with mesothelioma
in South East England in the period 2000–2004. 1985 of
the patients were males and 448 were females. 2207 of
these patients had died at the time of analysis. Out of
these, 2200 of the patients had their causes of death certi-
fied and these were identified and retained for analysis.
The remaining seven patients for whom we did not have
the causes of death were excluded from further analysis.
Table 1 shows that 87% of the mesothelioma patients had
mesothelioma mentioned on the death certificate. 6%
had no mention of mesothelioma but included lung can-
cer as a cause of death. Another 6% had no mention of
mesothelioma or lung cancer, but included an unspecified
cancer as a cause of death. Lastly, 2% had other causes of
death specified on the death certificate.
The proportion of death certificates that mentioned mes-
othelioma was dependent on age at diagnosis. It was 90%
in the age-group up to 69 years, 86% in the 70–79 years
age-group, and 78% in patients 80 years and older. Corre-
spondingly, the apparent misclassification as lung cancer
deaths (6% overall) and as unspecified cancer deaths (6%
overall) were highest in the 80+ years age-group at 11%
and 7%, respectively.
Discussion
Overall, most patients diagnosed with mesothelioma had
mesothelioma recorded on the death certificate. However,
about 12% of mesothelioma patients were certified as
dying from lung cancer or from an unspecified cancer and
this proportion increased with age.
Table 1: Analysis of certified causes of death in 2200 mesothelioma patients who had died.
Causes of death extracted from ICD version 10 coded causes of death in the death certificate record N %
Death certificate mentioned mesothelioma. 1905 87
No mention of mesothelioma. Death certificate mentioned lung cancer. 128 6
No mention of mesothelioma or lung cancer. Death certificate mentioned an unspecified cancer. 123 6
All other 44 2
Total 2200 100BMC Cancer 2009, 9:28 http://www.biomedcentral.com/1471-2407/9/28
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Since the introduction of the 10th version if the Interna-
tional Classification of Diseases (ICD), mesothelioma has
had a unique code (C45) which enables more complete
registration of mesothelioma as a cause of death. In the
previous revisions of ICD, mesothelioma deaths were
commonly assigned to code 163 (Malignant neoplasm of
pleura), 162 (Malignant neoplasm of bronchus and lung)
or 199 (Malignant neoplasm, unspecified site) [4].
A previous study from Scotland described the singular,
underlying cause of death in mesothelioma patients
before and after the introduction of ICD version 10 in year
2000 [4]. The specificity of the coding was greatly
improved from 40% of cases coded to 163 (Malignant
neoplasm of pleura) in ICD version 9 to 74% of cases
coded to a mesothelioma code (C45) in ICD version 10.
The present study extends the Scottish study of the ICD
version 10 coded underlying cause of death in 607 mes-
othelioma cases to 2200 mesothelioma cases and extends
the analysis to all the causes of death that are listed on the
death certificate.
Record linkage analysis, similar to the present study, has
been carried out for a variety of diseases, e.g. [5,6]. Com-
pared with many other diseases, the certification rate for
mesothelioma is relatively high. In the main, this is a con-
sequence of the poor prognosis and high fatality of mes-
othelioma.
We have not verified the mesothelioma cancer registra-
tions for the purpose of this study. It is possible that a pro-
portion of the mesothelioma cases were misclassified lung
cancers or metastases from other cancers. Such misclassi-
fication is, however, likely to be small, and could only
account for a small part of the deaths coded as lung cancer
deaths or deaths from unspecified cancers. This is because,
in the vast majority of patients with suspected malignancy
involving the pleura, most will now have biopsy confir-
mation and a recent validation study in relation to the
MESO-1 chemotherapy trial has shown a very high inci-
dence of correct diagnosis pre-mortem for mesothelioma
[7], due at least in part to the relatively recent availability
commercially of antibodies that show good specificity
and sensitivity for a mesothelial phenotype [8]. The likeli-
hood of people being managed without biopsy is further
decreased by the need for tissue diagnosis in relation to
any potential medicolegal consequence with regards to
occupational exposure to asbestos.
Mesothelioma patients may possibly die from any cause
of death. The 2% of cases with "All other" causes of death
included a variety of diseases and causes of death. The
main concern is not about these relatively few patients,
but the cases where the cause of death was attributed to
lung cancer or to an unspecified cancer. It is most likely
that many of these records erroneously omitted the men-
tion of mesothelioma as a contributory cause of death.
Conclusion
Incorrect death certification is a serious error, not least for
deaths that are caused by occupational or environmental
exposures. This analysis suggests that the official mortality
data may underestimate the true occurrence of mesotheli-
oma by around 10%.
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